Evaxion Biotech AS (EVAX)
2.64
+0.05
(+1.93%)
USD |
NASDAQ |
Nov 04, 16:00
2.64
0.00 (0.00%)
After-Hours: 16:51
Evaxion Biotech Research and Development Expense (Annual): 11.92M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 11.92M |
| December 31, 2022 | 17.06M |
| December 31, 2021 | 19.58M |
| Date | Value |
|---|---|
| December 31, 2020 | 10.90M |
| December 31, 2019 | 8.216M |
| December 31, 2018 | 3.729M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
8.216M
Minimum
2019
19.58M
Maximum
2021
13.53M
Average
11.92M
Median
2023
Research and Development Expense (Annual) Benchmarks
| Ascendis Pharma AS | 447.61M |
| Novo Nordisk AS | 4.710B |
| DBV Technologies SA | 60.22M |
| Adaptimmune Therapeutics PLC | 126.51M |
| Akari Therapeutics PLC | 5.45M |